Seipel Group
Seipel Group is an Australian clinical-research company that licenses its patented Urox® herbal bladder health formulations to supplement brands and retailers across women's, men's, and children's health segments, supported by 14 clinical trials and GMP-certified US manufacturing.
- Company typePrivate
- Founded1999
- HeadquartersAshgrove, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Seipel Group does
Seipel Group Pty Ltd is an Australian clinical-research and ingredient-licensing company that develops and commercializes patented herbal bladder health formulations sold under the Urox® brand family. Founded by Dr. Tracey Seipel (N.D.) and headquartered in Ashgrove, Queensland, the company has spent more than two decades building a proprietary three-botanical formulation (Equisetum arvense, Crateva nurvala, and Lindera aggregata) supported by 14 clinical trials, including multiple randomized, double-blind, placebo-controlled studies and a published Mechanism of Action trial. Its product portfolio spans three life-stage verticals: Urox® for women (postpartum, perimenopause, menopause), ProRox for men (bladder and prostate health), and Urox Junior for children aged 6+ (bedwetting). Each formulation is offered in multiple formats — capsules, powder blend, bulk ingredients, and finished bottled product — and is manufactured in GMP-certified US facilities.
The company's commercial model is purely B2B: it licenses its IP-protected Urox® formulations to supplement brands, health companies, and retailers through private label, white-label, and custom-formulation arrangements, and also sells bulk ingredients and finished products to manufacturing and distribution partners. Pricing is quote-based and not publicly disclosed. Go-to-market is driven by clinical-research documentation, participation in industry events such as the NBJ Summit, Expo West, and Pharmacy Connect, and sustained industry-award recognition (Telstra Best of Business, NutraIngredients, Export Awards). Seipel also maintains US sales and marketing operations alongside its Australian headquarters, signaling an export-led posture.
The company is privately held under founder leadership, with a small headcount (1–10) and no disclosed funding rounds, acquisitions, or institutional investors. Its strategic emphasis is on leveraging its clinical-evidence base and patent protection to win licensing partners rather than competing directly on branded retail shelves. Sustainability positioning — particularly the claim of significant disposable incontinence product waste reduction — has become an additional layer of differentiation in partner conversations.
Seipel Group firmographics
Firmographics- Name
- Seipel Group
- Legal name
- Seipel Group Pty Ltd
- Website
- https://seipelgroup.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Seipel Group is an Australian clinical-research company that licenses its patented Urox® herbal bladder health formulations to supplement brands and retailers across women's, men's, and children's health segments, supported by 14 clinical trials and GMP-certified US manufacturing.
- Ownership category
- akta.pro rank
Seipel Group industry classification
Industry- Product category
- Herbal Bladder Health Supplements
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Herbal & Botanical Supplements (CRADAGAD)
- akta.pro secondary industries
- Functional Foods & Supplement Formats (Gummies, Chews, Powders, Shots) (CRADAGAI), Botanical/Herbal & Adaptogen Functional Beverage Production (AFAFAFAF)
Keywords
Where Seipel Group is headquartered
LocationHeadquarters
- HQ city
- Ashgrove
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Seipel Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Licensing Royalties: License fees and royalties from brands adopting Urox® formulations for their product lines under private label or white-label arrangements.
- Bulk Ingredient Sales: Sale of bulk ingredient powder blend, capsules, and finished bottled products to manufacturing and distribution partners.
- Custom Formulation Services: Development of custom formulations to reflect unique brand requirements, with supporting documentation for regulatory compliance.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Seipel Group product offering
Product offeringCore offering
Seipel Group formulates, develops, and licenses clinically validated herbal bladder health products under its patented Urox® formulation. The company supplies bulk ingredient powder blends, capsules, and finished bottled products, and offers private label, white-label, and custom formulation services to supplement brands, health companies, and retailers worldwide. Its product range targets women's, men's, and children's urinary health needs.
Product overview
Seipel Group is a clinical research company specializing in patented, clinically validated bladder health formulations. The company offers three distinct products targeting different life stages: Urox for women (supporting postpartum, perimenopause, menopause, and post-menopause), ProRox for men (bladder and prostate health), and Urox Junior for children (bedwetting). All formulations are based on a proprietary herbal blend of Equisetum arvense (horsetail), Crateva nurvala, and Lindera aggregata. Products are available for licensing, private label, and custom formulation partnerships, offered in multiple formats including capsules, powder blend, and finished bottled products.
Differentiator
Problem solved
Functional benefit
Brands
- Urox: Award-winning bladder control formula for adults (women and men). Clinically validated in 14 trials, patent-protected formulation supporting bladder health.
- Urox Junior
- Prorox
Products and services
- Urox Clinically proven bladder health formulation for women, supporting bladder control during postpartum recovery, perimenopause, menopause, and post-menopause. Addresses pelvic floor, bladder tone, and bladder lining integrity through a proprietary blend of Equisetum arvense, Crateva nurvala, and Lindera aggregata.
- ProRox Bladder and prostate health formula for men, improving bladder control, reducing urgency and frequency, and supporting prostate health. Targets lower urinary tract symptoms including weak stream and nocturia.
- Urox Junior Gentle, clinically tested bedwetting formula for children aged 6 years and older. Helps reduce nighttime bedwetting and daytime accidents with natural ingredients in child-friendly delivery formats; 62% reduction in bedwetting reported in clinical trials.
Quantifiable outcome
- 90% of participants reported improvement in bladder control
- +7 more outcomes
Companies that use Seipel Group
Customer profileSegments3 records
Ideal customer profiles1 record
Seipel Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Seipel Group partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights5 records
Seipel Group competitors and assessment
Company assessmentBroad incumbents
- Astellas Pharma: Astellas markets Myrbetriq, the leading prescription overactive bladder therapy. As a large incumbent in bladder-health treatment, it represents the pharmaceutical standard-of-care against which Urox® is positioned as a natural alternative for consumers and brand partners.
Direct peers
- Thorne: Thorne is a premium practitioner-grade supplement brand built on clinical research and third-party testing. Its evidence-led, B2B-plus-DTC model and emphasis on condition-specific formulations make it a strong comparable for Seipel's clinical-validation-led positioning.
- Nature's Way: Nature's Way is a long-established US herbal and botanical supplement brand with broad condition-specific SKUs including urinary and prostate health lines. It competes in the same retail channels that licensees of Urox® typically target, making it a relevant shelf competitor.
- Azo (i-Health / Church & Dwight): Azo is the leading OTC consumer brand for bladder control, urinary tract health and yeast infections in the US, marketed directly to consumers. It is the most directly comparable counter-position to Urox in the same bladder-health category, competing for the same end consumer even though Seipel sells B2B rather than DTC.
- Integrative Therapeutics: Integrative Therapeutics (formerly Enzymatic Therapy) is a clinical-grade supplement manufacturer serving healthcare practitioners. Its practitioner-channel B2B model and clinical-evidence emphasis are closely aligned with how Seipel goes to market through licensees and bulk partners.
- Metagenics: Metagenics is a clinical-grade, practitioner-channel nutritional supplement manufacturer selling through licensed health professionals globally. It mirrors Seipel's evidence-led, B2B-style positioning and focus on condition-specific formulations supported by clinical research.
- Standard Process: Standard Process is a whole-food supplement company selling primarily through healthcare practitioners with a long R&D heritage. Its practitioner-channel B2B model, clinical orientation, and specialty-condition focus closely parallel Seipel's Urox® distribution approach.
- Gaia Herbs: Gaia Herbs is a vertically integrated herbal supplement manufacturer with a certified-organic farm and a strong clinical-validation story. Its herbal, single-condition SKU strategy and focus on clean-label certifications map closely to Urox®'s positioning in the herbal supplement segment.
Regional players
- Blackmores: Blackmores is Australia's largest supplements brand with a broad condition-specific portfolio including urinary and women's health lines. As a regional incumbent in Australian natural health, it competes for the same licensee and retail customers in Seipel's home market.
- Flordis: Flordis is an Australian evidence-based botanical medicine company (part of the Soho Flordis King International group) marketing clinically researched herbal brands such as Femular. It is a relevant Australian/Asia-Pacific comparable in clinically validated herbal supplements.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Seipel Group social profiles
Digital presenceSeipel Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seipel Group leadership team
Management profileNumber of profiles
Profiles2 records
Seipel Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seipel Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seipel Group
What does Seipel Group do?
Seipel Group formulates, develops, and licenses clinically validated herbal bladder health products under its patented Urox® formulation. The company supplies bulk ingredient powder blends, capsules, and finished bottled products, and offers private label, white-label, and custom formulation services to supplement brands, health companies, and retailers worldwide. Its product range targets women's, men's, and children's urinary health needs.
Is Seipel Group a public or private company?
Seipel Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Seipel Group founded?
Seipel Group was founded in 1999. It employs 1 to 10 people.
Where is Seipel Group based?
Seipel Group is headquartered in Ashgrove, Australia, in the Oceania region.
How does Seipel Group make money?
Three revenue lines are on record. Licensing Royalties are the primary driver. The others are bulk Ingredient Sales and custom Formulation Services.
Who are Seipel Group's main competitors?
Astellas Pharma is listed as a broad incumbent. Direct peers are Thorne, Nature's Way, Azo (i-Health / Church & Dwight), Integrative Therapeutics, Metagenics, Standard Process and Gaia Herbs. Regional players are Blackmores and Flordis.
Does Seipel Group have an API?
No public API is recorded for Seipel Group.
What industry is Seipel Group in?
Seipel Group's product category is Herbal Bladder Health Supplements. Its primary akta.pro industry code is CRADAGAD, Herbal & Botanical Supplements, with a secondary code of CRADAGAI, Functional Foods & Supplement Formats (Gummies, Chews, Powders, Shots). Its NAICS code is 325411 and its SIC code is 2833.